Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Advertisement

Related Content

Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing
Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine
Advair Competition: Teva’s AirDuo Approved But Not Therapeutically Equivalent
Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid
Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market
Keeping Track: Mitsubishi ALS NDA; Opko’s Rayaldee Approval; Avycaz Label Extension
Remicade Biosimilars: Samsung Looks To Follow Celltrion's Footsteps
Biosimilar Denied: Hospira's Retacrit Could Head Back To FDA In First Half 2016
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel